Phaseline

Companies › Editas Medicine

Editas Medicine: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 1; Hematology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
EDIT-301 (renizgamglogene autogedtemcel, reni-cel)
ex vivo base editing of hematopoietic stem cells targeting BCL11A to increase fetal hemogl
BCL11APhase 1Sickle Cell Disease; Transfusion Dependent Beta Thalassemia–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04853576EDIT-301 (renizgamglogene autogedtemcel, reni-cel)Phase 1Sickle Cell DiseaseHematologyAug 2025
NCT05444894EDIT-301 (renizgamglogene autogedtemcel, reni-cel)Phase 1Transfusion Dependent Beta ThalassemiaHematologySep 2025

From the company's SEC filings

Cash and short-term investments of $190m on 2026-09-30; operating cash outflow about $99m a year; runway about 23 months at that burn, to Aug 2028

Press releases filed as 8-K in the last year:

Specialist investors

Held by 11 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

BCL11A (1)

Companies with the same targets

Vertex Pharmaceuticals

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.